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Abstract
Legionella pneumophila is a Gram-negative bacteria that cause community-
acquired pneumonia in very common circumstances. Although it is rare to develop 
hospital-acquired pneumonia due to Legionella pneumophila, there are cases where 
the infection appears during its presence in the hospital environment or because of 
the existence of Legionella outbreaks. It is important to mention that the coloniza-
tion of this organism is mostly found in some hospital water supplies. The preven-
tion of the spreading of this nosocomial pathogen is crucial for the hospital setting 
by identification of the bacteria. Using surveillance and control of infection, as well 
as maintaining beneficial isolation of those patients with the disease, could prevent 
the dissemination of this rare infection among hospitalized patients that are highly 
vulnerable. The treatment should be effective and according to the standard of care 
guidelines. The initiation of empiric antibiotic therapy is critical once the pathogen 
is suspected to be the etiology of pneumonia.
Keywords: legionella pneumonia, hospital, hospital-acquired, prevention, clinic, 
epidemiology, pneumonia, management
1. Introduction
Legionnaires’ disease is a severe type of pneumonia. It is typically acquired by 
inhalation of contaminated water containing the Legionella pneumophila gram-
negative bacteria. The severe pneumonia occurs most frequently in susceptible 
patients (i.e., former or current smokers, chronic diseased patients, immunosup-
pressed patients and those >50 years of age) [1]. The most commonly transmis-
sion of contaminated water is from showerheads, some medical equipment (i.e., 
respiratory devices), cooling towers, hot tubs, hydrotherapy equipment’s and/
or decorative water fountains [2]. Several countries have different recommended 
strategies for the prevention of Legionella pneumophila dissemination. They 
measure dangerous concentrations and they use water sampling frequency with 
activation of alerts of the L. pneumophila levels. These strategies always depend 
on local regulations and the geographic variations. Although, the regulations 
have some differences, all of them include three principles: (1) the supervision of 
critical spots (which are locations in a hot water installation where water stays, 
and makes the L. pneumophila in a suitable growth temperature range for some 
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time), (2) avoiding water stagnation in specific parts of the system and the preven-
tion of the proliferation and (3) requirement of a sufficiently high temperature 
to prevent the growth and spread of L. pneumophila. The European Working 
Group for Legionella Infections recommends that the total volume of the storage 
tank needs to be heated to 60°C for at least an hour a day, depending on the risk 
of spreading [3]. In the United Kingdom, the Department of Health recommends 
maintaining hot water temperatures at a temperature lever >55°C and cold water 
<20°C to prevent the proliferation of L. pneumophila in the water systems. Also, 
when cooper and silver ionization is introduced to a new building in conjunction 
with appropriately managed water, there is a better control in the dissemination of 
the bacteria [4]. It is important to mention that Legionella prevention should start 
with the correct design and construction of the water networks. During facilities 
renovations or a construction of a new one, the pipe runs should be as short as 
practical [5]. Usually, the evaluation of water systems for Legionella is until after 
the disease has been identified and confirmed. Thus, it is recommended a practical 
approach of periodic testing for Legionella, along with proper water treatment to 
avoid large-scale outbreaks [6]. In addition of water management in all health care 
facilities, it is crucial to have better methods for detecting Legionella in the water 
systems and in some of the clinical specimens to enhance the preventive strategies 
and the clinical diagnosis. In the United States, the CDC developed a toolkit to for 
all Medicare-certified healthcare facilities to assist in the water management in 
order to reduce the growth and transmission of the bacteria [7].
One of the preventive methods is to run cultures and other diagnostic methods 
to assess the rate of spreading of the gram-negative bacteria. According to a study 
made in Pittsburgh, Pennsylvania, water cultures are more significantly more 
sensitive than collected swab cultures in detecting Legionella pneumophila. This 
study was done due to an outbreak of nosocomial Legionnaires’ disease among 22 
veterans in the Veterans Affairs Pittsburgh Healthcare System [8]. The reality is 
that testing for atypical pathogens in patients is poorly standardized in a realistic 
scenario, especially in low-income countries where some guidelines are needed for 
the implementation of a suitable diagnosis. One of the major implications of this 
approach is the wide heterogeneity across continents and countries [9].
The risk management in hospitals of Legionella pneumophila seems to be under-
represented in the literature. A literature review done by Leiblein, et al., stated that 
further research in the field of risk management and prevention of Legionella in the 
water systems must be perform [10].
2. Epidemiology
All Legionnaires’ disease cases are reported to the Centers for Disease Control 
and Prevention (CDC). In 2015, a national surveillance data confirmed a total of 
2809 Legionnaires’ disease cases. Those cases were reported to the CDC from 21 
jurisdictions, including 85 definite (3%) and 21 (17%) possible health-care associ-
ated cases. This last high rate marks the importance of case prevention among 
health institutions and the implementation of effective water maintenance pro-
grams, as well as a proper case identification. The most frequent health-care facility 
associated with this disease was a long-term care facility, with 80% of the definite 
cases [11]. In the United States, the reported cases of Legionnaires’ disease have 
increased nearly 4.5 times since the year 2000. It could be related to the increased 
susceptibility of the population, the access to new diagnostic methods or a com-
bination of both [12]. One of the main causes of transmission is closely related to 
professions where there is nebulization with water, mainly among workers with 
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long term exposure. The outbreaks tend to be seasonally, especially in the hottest 
months of the year (May–August) [13].
Although, it is historically associated with healthcare institutions, it is impor-
tant to mention that some retirement homes are also at risk of dissemination of 
the disease. The healthcare-associated cases represent a proportion of cases in 
elderly patients (>60 years of age). Drinking contaminated water can contribute to 
outbreaks. De Filippis, et al., collected hot water and biofilm samples from shower-
heads of retirement homes. Then they were tested by culture method. It resulted in 
140 hot water and biofilm samples collected, with Legionella found in 36.8% of the 
samples. The results suggested that the colonization of these retirement homes is 
occasional, but further studies were suggested [14].
Although there are limited data available, the incidence reported is around 
10–15 cases detected per million population. From them, 75–80% are >50 years and 
60–70% are male with underlying chronic diseases [15].
Nevertheless, the prevention of Legionella still remains a critical issue, even in 
healthcare facilities where monochloramine disinfection has been introduced. It is 
documented that monochloramine has a better impact that free chlorine alone on 
Legionella control [16].
Although, this makes that continuous treatments with low monochloramine 
doses induced a viable but non-culturable state of Legionella. A study made by 
Casini, et al., obtained water and biofilm samples and isolated Legionella with the 
use of standard procedures. It emphasized the importance of keeping an appropri-
ate and uninterrupted monochloramine dosage to ensure the control of L. pneu-
mophila colonization in water supplies for hospitals [17].
Another chemical disinfection method used in water systems is the chlorine 
dioxide. It is reported that the duration of the effective protection of chlorine diox-
ide is reliable and could support the process in the framework of risk management 
activities in hospitals. This was documented by Vincenti, et al., where the duration 
of chlorine dioxide method in eradicating Legionella was analyzed in a large hospi-
tal in Rome. The observation was made from samples takes between 2011 and 2018. 
It concluded that Legionella was never detected at 4 years of follow-up [18].
3. Pathophysiology
Legionella pneumophila can be found in biofilm formations, as a single microbe 
in freshwater and manmade devices such as, shower heads, air conditioning sys-
tems, cooling towers and water fountains. This intracellular pathogen is the caus-
ative agent of a severe form of pneumonia known as legionnaires’ disease [19]. Once 
transmission to the human lung is established through inhaled infectious aerosols, 
L. pneumophila is engulfed by the macrophage where it replicates, causes inflam-
mation and consequently pneumonia [20]. Jäger et al., showed, through human 
lung tissue explants that Legionella pneumophila damage to lung is characterized by 
“destruction of its connective tissue, proteinaceous exudate and delamination of 
alveoli”, [21] thus the physical symptoms.
L. pneumophila obtains shelter from harsh environmental conditions by forming 
an advantageous relationship with unicellular protozoa. Besides shelter it provides 
nutrients for survival and infectivity. Once L. pneumophila utilizes all the protozoa’s 
nutrients, it exits the host as bacterium capable of thriving within monocytes and 
macrophages in case of inhalation through the infected particles. Once inhaled, the 
bacteria reach the alveoli, enter alveolar macrophage through coiling phagocytosis 
or normal phagocytosis, and cause legionnaires’ disease. Previous studies have 
shown that this is thanks to genes that encode for effector proteins with eukaryotic 
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characteristics that are injected through the legionella containing vacuole. This is 
known as molecular mimicry [19, 22]. Cazalet et al., found 30 genes of L. pneumophila 
that encoded for proteins with high resemblance to eukaryotic proteins and another 32 
genes involved in protein-protein interactions within eukaryotic domains [23].
3.1 Strategy
Legionella’s life cycle consists of two main phases. In order to survive against 
harsh environmental conditions, legionella enters a “reversible dormant state”, 
known as the viable but not culturable state (VBNCS) [24] When environmental 
conditions improve, like in the case of phagocytosis by Acanthamoeba castellanii, 
the bacterium represses its virulent traits and goes into its exponential phase, in 
which it replicates within the protozoa [6]. This process of replication takes round 
15 hours to complete [25]. Once lack of nutrients and environmental stress strikes, 
L. pneumophila coordinates its differentiation to the mature intracellular form 
(MIF) and the stationary phase form (SPFs), both with virulent traits character-
ized by high motility and cytotoxicity and proceeds to lyse the cell and infect cells 
in proximity. Although studies are lacking on the mechanisms by which the host 
cell is lysed by the bacterium [24, 25]. SPFs present flagella, loose outer membrane, 
and a well-defined inner membrane, while MIFs typically appear as stubby rods 
with complex envelope, both being able to colonize alveolar macrophages [24]. 
Legionella accomplishes this physiologic and morphologic change by the coordina-
tion of LetA/LetS and sigma factors RpoS and FiA [26]. When there is low avail-
ability of amino acids, RelA, a ribosomal enzyme, synthetizes alarmone ppGpp 
(guanosine pentaphosphate) with subsequent activation of sigma factor RpoS and 
LetA/S. LetA/S work in conjugate to induce the expression of CsrB homologues 
which are RNAs that can sequester CsrA. CsrA expression represses the flagel-
lar sigma factor fliA, which translates into a non-motile pathogen, with reduced 
virulence [27]. Studies have shown that through legionella’s exponential phase, the 
bacterium increases its resistance against heat, and antibiotics [24].
3.2 Legionella and the host cell
The key mechanism for L. pneumophila inert ability to survive against the harsh 
intracellular environment is its secretory system. Legionella pneumophila uses a 
type IVB secretion system (T4BSS) encoded by the delayed in organ trafficking/
intracellular multiplication gene [28]. The T4BSS is involved in endocytic and 
secretory pathways as well as ubiquitination, host lipid metabolic exploit and cell 
death prevention by enabling the formation of the vacuole in which the bacterium 
resides for multiplication [29]. When a phagosome is formed, it matures, acidifies, 
and fuses with the lysosome. The phagolysosome can digest the contained organism 
through different bactericidal peptides, reactive oxygen species (ROS) and hydro-
lytic enzymes. Once the pH of the phagolysosome achieves certain acidity, these 
hydrolytic enzymes get activated leading to the destruction of the pathogen [28]. 
The acidification is accomplished by a proton pump ran by ATP hydrolysis called 
the vacuolar-ATPase (v-ATPase). This v-ATPase is made up by the trans-membrane 
domain V0, and the cytosolic V1 domain, which translocate H
+ across the lipid 
bilayer and hydrolyzes ATP used for proton translocation respectively [30]. Prior 
research suggests that Legionella pneumophila secretes SidK, an effector protein that 
halts acidification of the phagolysosome by interaction with v-ATPase in early stages 
of infection. Zhao et al. showed that Binding of Sidk to the v-ATPase decreased its 
affinity, although only by 40% of v-ATPase activity, suggesting the presence of 
other effector proteins [30].
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A key element on the formation of the LCV is the ability to disrupt vesicle traf-
ficking between the ER and the Golgi apparatus. This interception of vesicle is what 
gives the LCV the ability to expand for replication and its ER-like properties [31].
Multiple studies show that L. pneumophila can accomplish this by targeting 
Rab1, a member of the Ras superfamily GTPases. Rab proteins are essential to the 
secretory pathway, and these proteins are localized in specific intracellular mem-
branes, mainly ER and Golgi [32]. Control over inactive GDP-bound and active 
GTP bound GTPases are controlled by Guanine nucleotide exchange factors (GEFs) 
and GTPase-activating proteins (GAPs). This is where the DrrA/Sidm effector pro-
tein plays its role. Due to its high affinity for GDP-bound Rab1, DrrA/Sidm acts as a 
GEF, exposing its master molecular switch allowing for the recruitment of vesicles 
[33]. Furthermore, previous studies have suggested that the N-terminal region of 
DrrA is involved in AMPylation reaction that is essential for the localization and 
maintaining of Rab1 in the LCV by avoiding Rab1 deactivation by GAFs [34]. These 
reactions are reversed through SiD and Lem3 effector proteins respectively. Further 
modification of Rab1 is accomplished by SidE, SdeA, SdeB, and SdeC effector 
proteins through a complex ubiquitination process.
L. pneumophila avoids host cell death to allow for replication by upregulation 
BCL-2 and blocking the activity of BNIP3 and BCL-Rambo. The only implicated 
factor in inhibition of BNIP3 and BCL-Rambo in past research studies had been 
only SidF. A recent study suggests that there is still unexplored territory pertain-
ing to avoidance of host cell apoptosis. Speir et al. showed with mutant strains of 
legionella lacking SidF, that there was not any significant increase in the rate of cell 
death, suggesting presence of other effector proteins [35].
Past studies have shown that the LCV exploits the hosts lipid metabolism to 
generate a vacuole with Golgi apparatus characteristics to facilitate the hijacking 
of vesicles trafficked between the ER and the Golgi apparatus. The LCV acquires a 
composition like that of the Golgi apparatus by enriching the LCV with PtdIns4p 
a phosphoinositide through the T4BSS and SidF, LepB, AR1f, LecE, LpdA effector 
proteins. SidF in conjunction with host 5-phosphatase OCRL1 reduces PtdINs(3,4)
P2 into PtdIns4P, while LpdA synthesizes phosphatic acid and LecE activates this 
phosphatidic acid to produce diacylglycerol, which lead to the recruitment of host 
Kinase D proteins with consequent recruitment of PI4IIIKB and production of 
PtdIns4P [35].
4. Diagnosis
4.1 Urine antigen “the rapid test”
Urinary antigen test can be used to detect Legionella. This method requires 
monoclonal antibodies that recognize lipopolysaccharide antigens from Legionella 
pneumophila serogroup 1 in a urine sample. Results can be available in the next 
few minutes, giving it an advantage for rapid diagnosis. Sensitivity ranges from 
69 to 100%, and specificity ranges from 99 to 100%. One main disadvantage from 
this test is that it overlooks the detection from other serogroups and species of 
Legionella. This can be related that about 8% of patients infected with Legionella 
fail to excrete urine antigens [36–38].
4.2 Microbiological culture “the gold standard”
Isolation by culture continues as the gold standard for Legionella disease. It is 
superior to identify all of the known species and serotypes of Legionella. Sensitivity 
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can get up to 81% and specificity range from 99%. A variety of samples from the 
lower respiratory tract can be used for culturing, the most commonly use is sputum. 
Although in these patients the disease is developed as an atypical infection, the 
majority of them produce little or no sputum at all. Other acceptable specimens 
used are fluid from bronchial aspiration, bronchial alveolar lavage, and pleural 
fluid. The less used are lung tissue taken from a biopsy. The most successful and 
selective isolation media used for Legionella is the buffered charcoal yeast extract 
agar, also known as BYCE agar. A positive growth is available within 3–5 days, 
although when it co-exists background flora, will require addition treatment to 
reduce it, this can delay result up to 2 weeks [39].
Environmental isolation can be also obtained by culture test but requires a vari-
ous preparation techniques to decrease the presence of environmental flora from 
samples, as well as different media. [37, 40]
4.3 Direct fluorescent antibody “the confirmatory technique”
The using of this test helps to confirm a suspected overgrowth of Legionella in 
a culture. After 3 days of incubation, a direct fluorescent antibody applies to the 
specimen staining the viability to growth. Sensitivity for L. pneumophila sero-
group-1 ranges up to 70% and specificity is 99%. Quick results can be possible to 
obtain, but requires expert techniques [41–43].
5. Treatment
For Legionella pneumophila, a high-level of suspicion and prompt initiation of 
adequate antimicrobial therapy is critical to improve clinical outcomes. Failure to 
administer proper antimicrobial therapies at an early stage of the infection has been 
associated with higher mortality rates [44]. The correct choice of antibiotic depends 
not only in its in vitro bactericidal or bacteriostatic activity, but also in its ability 
to penetrate the cell membrane of host tissue. This is because Legionella resides 
within host tissue cells. The preferred families of antibiotic are the fluoroquinolones 
(levofloxacin and moxifloxacin) and the macrolides (azithromycin) [45, 46].
The situations suggesting pneumonia by Legionella are: Gram stains of respira-
tory samples revealing many polymorphonuclear leukocytes with few or no organ-
isms, hyponatremia, pneumonia with prominent extrapulmonary manifestations 
(diarrhea, confusion, etc.), failure to respond to administration of beta-lactams, 
aminoglycoside antibiotics, or both and recent traveling [46–48]. When treating 
Legionella pneumophila, the first choice of antibiotics should be macrolides or qui-
nolones. Quinolones are more active than macrolides. Sometimes may be preferred 
in other patients whom drug interactions could be a problem. For example, in 
immunocompromised patients the potential for interaction with medications like 
cyclosporine or protease inhibitors is documented to be in a less with quinolones 
than with macrolides.
Azithromycin is the drug of choice for children with suspected or confirmed 
Legionella disease. Erythromycin is not often used now even though it is highly 
effective, but its use has been related with considerable side effects (i.e., gastro-
intestinal and ototoxicity), especially when used intravenously. Azithromycin 
has been shown to be the more active macrolide against Legionella pneumophila 
followed in order of activity by erythromycin, roxithromycin, dirithromycin, and 
clarithromycin [44, 47, 49]. Azithromycin is the safest macrolide. The advantage 
is due to its good intracellular penetration, bactericidal activity, proven clinical 
efficacy, short duration of treatment and good safety profile. Furthermore, the 
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15-membered lactone ring of Azithromycin does not interact with cytochrome P450 
(CYP) 3A4 isoenzymes (i.e., cyclosporine). Unlike the other types of macrolides, 
this reduces the potential for drug interactions. The initial course should be intrave-
nously administered. After a good clinical response is detected, it can be switched to 
the oral route. In patients with severe disease or unresponsive to monotherapy, the 
addition of rifampin is recommended [45, 50]. The recommended Azithromycin 
dose is 500 mg IV/PO q24h for 5 days. Alternatives are: Clarithromycin 500 mg IV/
PO q12h for 10 days and Erythromycin 1 g IV q6h or 500 mg PO q6h [47].
Quinolones have all been shown to inhibit the intracellular growth of  
L. pneumophila. The most potent inhibitors of intracellular multiplication, in 
order of decreasing activity, were levofloxacin, ciprofloxacin, and ofloxacin [45]. 
Levofloxacin stops multiplication of bacteria by preventing the reproduction and 
repair of their genetic material (DNA) and it appears to be associated with a more 
rapid resolution of symptoms, a shorter time to clinical stability and consequently 
shorter length of hospital stay then the macrolides. Levofloxacin, either 500 mg 
PO/IV qd for 10 days or 750 mg PO/IV qd for 5 days, can cure most of the patients 
and is becoming the antibiotic of choice for Legionella disease [45, 49, 51].
Other alternatives include Doxycycline 100 mg PO/IV q12-24h for 7–21 days or 
sulfamethoxazole/trimethoprim DS 800 mg/160 mg 1–2 tabs PO q12h or 20 mg/kg/
day IV q6-12h for 7–10 days [47, 49]. Rifampicin is very active against extracellular 
and intracellular Legionella spp. In the clinical setting, monotherapy is not recom-
mended. In case Rifampicin resistance emerges, it has been reserved for adjunctive 
therapy in severe cases of Legionella infection. Another limitation of Rifampicin is 
the potent induction of cytochrome P450 enzyme system and the potential for drug 
interactions [45].
The usual duration of therapy for most antibiotics is 5–10 days. This is often 
adequate to completely treat patients with Legionella infection. Although, a dura-
tion of therapy up to 3 weeks may be considered in immunocompromised patients 
or in patients with severe disease or with other pre-existing health conditions 
(chronic heart, lung, liver or renal disease, diabetes mellitus, alcoholism, malig-
nancies, and asplenia) [44]. Patients should be switched from intravenous to oral 
therapy when they are hemodynamically stable and present a clinical improvement 
and, also, if they are able to ingest medications and have a normally function-
ing gastrointestinal tract. Before discontinuation of therapy the patients should 
be afebrile for 48–72 hours and should be have at least one criteria for clinical 
stability (Temperature ≤ 37.80°C, heart rate ≤ 100 beats/minutes, respiratory 
rate ≤ 24 breaths/minutes, systolic blood pressure ≥ 90 mm Hg, arterial oxygen 
saturation ≥ 90% or pO2 ≥ 60 mm Hg on room air, normal mental status and ability 
to maintain oral intake). Patients should be discharged home as soon as they are 
clinically stable, and they have no other medical problem. Additionally it is impor-
tant to have a safe environment for continuity of care. The inpatient observation 
while receiving oral therapy is not required [44, 51, 52].
6. Prevention
Even though Legionella pneumophila is a very uncommon etiology of nosocomial 
infection, the CDC recommends a high degree of suspicion when there are cases of 
nosocomial pneumonia with unknown etiology [53]. The presence of warm water 
is suitable for the growth of the bacteria (20–45°C). It is known that Legionella 
colonizes hot water distribution systems in 12–70% of hospitals in some geo-
graphic areas. For example, a study made in Hungary showed that Legionella was 
found in 90% of some surveyed hospitals that were >30 years old [54]. Also, it is 
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documented that Legionella can survive at higher temperatures (>60°C) but keep-
ing a hot water at that range can cause third-degree burns in some patients (1 sec-
ond of exposure to hot water in children, and 5 seconds of exposure to hot water in 
adults). It is important that hospital regulations focus on maintaining proper water 
temperatures [55].
The frequent monitoring of hospital water system is mandatory when there is 
Legionella pneumonia documented in a patient hospitalized, or even when there 
is suspicion of Legionella. Water sample cultures are the most prevalent method 
for ascertaining colonization of water. The interpretation of Legionella testing can 
vary from geographical area, but some facilities can act and start the management 
of Legionella contamination when the culture results show a level of detection of 
1 CFU/mL [56].
A water management program is indispensable for Legionella prevention, and 
it should be implemented in every hospital since the incidence has been rising up 
in the United States. A survey developed in Minnesota in 2017, was applied in 137 
acute-care, critical care, and long-term hospitals. Only 84 surveys were returned 
and 3 were incomplete and excluded from the analyses. From them, 27% of the 
hospitals had a pertinent water management program. The 7% of those facilities 
measured pH at which cold and hot water were stored. The temperature range of 
the hot water storage was reported to be 42–62°C. All of the hospitals were supplied 
by community drinking water sources. Less than 5 used secondary disinfection 
systems (i.e., reverse osmosis, ultraviolet light, or chlorine). Also, only 21% of the 
responding facilities have reported to regularly test the water for the presence of 
Legionella [57]. They concluded that significant water management should be put 
into practice to protect patients from nosocomial Legionella [58].
In some other countries like Italy and Australia have developed programs for 
control and preventive measure for legionellosis. In Northern Italy, the water 
systems are routinely tested for Legionella. A questionnaire was applied to 739 hos-
pitals, and 178 were completed. It showed that 97% of the hospitals do routine tests 
for the presence of Legionella in water, and 62% detected a positive result. The most 
common control measure is disinfection of water systems, mostly with thermal 
shock and chlorine dioxide [59]. Also, the implementation of a water safety plan 
and disinfection with monochloramine prevented legionellosis in another hospital 
in Catania, Italy. The results after 3 years of application have proven to be highly 
effective in controlling the growth of Legionella and thus preventing nosocomial 
infections [60].
In Brisbane, Australia, they use genomic epidemiological methods to execute a 
rapid and effective water treatment to characterize and eradicate L. pneumophila. 
This was started to be used due to a background of two proven nosocomial cases of 
L. pneumonia. The trace of the whole genome sequence analysis was initiated from 
isolates of affected patients and a prospective isolated were collected from hospital 
water distribution systems. The aggressive intervention to resolve this included the 
closure of the hospital, scalding of the water system with 60°C for 10 minutes, and 
treatment with alkaline detergent and 10 mg/L free chlorine, as well as the instal-
lation of in-line chlorinator systems and intensive monitoring for the presence of 
LPSG1 in water specimens. The combinations of all these approaches proved to be a 
good support in the management of Legionella contamination [61].
7. Conclusions
Legionnaires’ disease is a potential preventable disease. The access to clean 
water should be essential for all the hospital environments, though, Legionella 
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pneumophila is quite atypical. The implementation of certain methods like avoiding 
critical spots and the prevention of water stagnation will help to decrease the risk 
of proliferation of the gram-negative bacteria, as well as its growth and spreading 
throughout the healthcare facilities. Most hospital water systems are complex and 
different one from another, and this is a reason for maintenance of an adequate 
temperature, such as >60°C water temperature is recommended. Though, the 
prevention of damage to patients (third-degree burns) should be taken in consid-
eration. This could be an alternative for prevention of the bacterial dissemination. 
The recalling in the pathophysiology of the bacteria will help us understand the 
natural history of the disease and thus comprehend our best choice for diagnosis 
and treatment. The diagnosis of patients with Legionella pneumophila is also quite 
important, and the microbiological culture should be used as a gold standard. The 
treatment needs to be initiated as soon as Legionella is suspected, and the patients 
should be placed in isolated rooms. Failure to starting the treatment will increase 
the risk of mortality among the patients. Further studies should be done to evaluate 
strategies of prevention of dissemination of the disease in all healthcare facilities, 
including the successful approaches that have been already performed in some other 
countries.
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